Our study is based on the data from SU.VI.MAX 2 study, which is an additional observational follow-up study, organized 5 years after the end of the initial SU.VI.MAX trial. The initial SU.VI.MAX trial was a randomized, double-blind, placebo-controlled primary prevention trial assessing the efficacy of a daily antioxidant supplementation in the incidence of cardiovascular disease and cancer. Eligibility criteria of SU.VI.MAX participants were described in previous publication [21–23]. This initial trial was launched in 1994–95 and had a planned follow-up of 8 years (until 2002).